Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Trial results promising, but DKA still a concern with use of new once-daily pills.
Read More »Two New Treatments Offer Type 1 Patients Greater Weight Loss and A1c Reduction
Ertugliflozin, An SGLT-2, Meets Goals in Two Phase 3 Trials
The investigational sodium/glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin (Merck), being developed to improve glycemic control in adults with type 2 diabetes, met the primary outcomes in two yearlong phase 3 trials, VERTIS SU and VERTIS SITA2.
Read More »SGLT-2 Inhibitors Safer and More Effective Than DPP-4s For Heart
New study finds lower occurrence of heart failure in older people with type 2.
Read More »EASD: SGLT-2/GLP-1 Combo Better Than Monotherapy
Trial finds improvement in control and weight loss.
Read More »Effects of SGLT-2 Inhibitors On UTIs and Genital Infections
Lowering HbA1c worth the risk of urinary tract and genital infections?
Read More »Even More Protection for the Kidneys With An SGLT-2 Inhibitor (And a comment from George Bakris, MD)
New data from the EMPA-REG-OUTCOME study provide more evidence of the renoprotective effects of empagliflozin in patients with type 2 and cardiovascular disease.
Read More »George Bakris Part 2, SGLT-2 Inhibitors and the Diabetic Kidney
Dr. George Bakris talks with Diabetes in Control Publisher Steve Freed during the ADA 77th Scientific Session in San Diego about the possible kidney benefits for those using SGLT-2s.
Read More »Jaime Davidson Transcript
Dr. Davidson discusses new diabetes drugs and their impact on patient health, including DKA; new combination drugs; and the expensive side effects of sulfonylureas.
Read More »Dr. Jaime Davidson Full Interview
In this Exclusive Interview, Dr. Davidson discusses his thoughts on new drugs and their impact on patient health, such as DKA.
Read More »Use of SGLT-2 inhibitors As Adjunct to Insulin In People with Type 1 Diabetes
Apart from Sotagliflozin’s use in the treatment of people with type 2, SGLT-1 and SGLT-2 inhibitors effects on type 1 currently being explored.
Read More »